Novalis Invests in Enzyre to Support Development of Enzypad, a Breakthrough Hand-Held Diagnostic and Monitoring Device
Novalis Invests in Enzyre to Support Development of Enzypad, a Breakthrough Hand-Held Diagnostic and Monitoring Device
07/27/20, 6:04 AM
Location
nijmegen
Industry
medical
biotechnology
health care
Enzyre, a developer of breakthrough diagnostic technology to bring the lab to the patient, announced today that Novalis Biotechnology Incubation, through its seed fund, participated as co-financer in the Euro 1.4 million Corona Bridge Loan granted by the Dutch government in support of innovative start-ups and scale-ups.
Company Info
Location
nijmegen, gelderland, netherlands
Additional Info
Enzyre is a spin-out from Radboud University Medical Center in The Netherlands founded by Waander van Heerde and Guido Maertens. The Company aims to develop a diagnostic device to provide patients with the flexibility to assess their coagulation status regardless of where they are. Enzyre's platform requires a small volume of blood to measure up to sixteen reactions simultaneously with high sensitivity and specificity without any laboratory infrastructure, at home, on the road or in a critical care setting. This offers enormous benefits to patients: avoid crisis situations driven by changes in coagulation status, provide ease of mind for patients, empower patients to optimize treatment themselves, be a quick turnaround tool in the clinical setting, reduce GP consultation visits and, as a personalized diagnostic tool, offer great support in a telemedicine setting.